Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer’s Disease in Greater China